IGF::OT::IGF DETECTION, ISOLATION, AND ANALYSIS OF SINGLE CTCS

IGF::OT::IGF 检测、分离和单个 CTCS 分析

• 批准号: 8738158
• 负责人: MARK LINDER
• 金额: $ 29.97万
• 依托单位: PGXL TECHNOLOGIES, LLC
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-13 至 2014-06-12
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8738158
• 关键词: Antigens; Biological; Cancer Diagnostics; Cells; Characteristics; Clinical Research; Contracts; Detection; Development; Diagnostic; Harvest; Human; Legal patent; Methods; Molecular Analysis; Neoplasm Circulating Cells; Phase; Process; Recovery; Reproducibility; Small Business Innovation Research Grant; Specimen; Subgroup; System; Systems Analysis; Technology; anticancer research; base; clinical Diagnosis; extracellular; new technology; novel

The objective of this project is to deliver a fully integrated CLIA-certified technology that provides diagnostic characterization of individually identified CTC¿s harvested from human specimens. We will use a novel patented chip-based dielectrophoretic-controlled isolation process (DEPArray) to identify and isolate single CTCs while maintaining their functional biological integrity. Using this technology we have developed a strategy for classifying CTCs into defined subsets with identifiable characteristics useful for clinical research and diagnosis. The specific tasks for this Phase I contract are to: 1) Establish a robust method for comprehensive detection and isolation of single circulating tumor cells 2) Define and isolate specific subsets of CTCs based on extracellular antigen expression 3) Demonstrate the ability to perform molecular analysis on single cells isolated from subgroups of CTCs 4) Demonstrate reproducibility of an integrated ¿CTC Detection, Recovery, and Analysis¿ system This SBIR contract will enable development of a fully-integrated and robust cell-identification and separation system to support CTC cancer research and diagnostics. This novel technology promises to revolutionize the identification of new subsets of CTCs and also assign clinically useful characteristics, such as metastatic potential, to each subset of cells.

该项目的目标是提供一种完全集成的CLIA认证技术，该技术可对从人体标本中采集的单独识别的CTC进行诊断表征。我们将使用一种新型的专利芯片扩散控制分离工艺（DEPArray）来识别和分离单个CTC，同时保持其功能生物学完整性。使用这种技术，我们已经开发了一种策略，用于将CTC分类为具有可识别特征的定义子集，这些子集可用于临床研究和诊断。第一阶段合同的具体任务是： 1)建立一种稳健的单循环肿瘤细胞综合检测和分离方法 2)基于细胞外抗原表达定义和分离CTC的特定亚群 3)证明对从CTC亚组中分离的单细胞进行分子分析的能力 4)证明集成的<$CTC检测、回收和分析<$系统的重现性 该SBIR合同将开发一个完全集成和强大的细胞识别和分离系统，以支持CTC癌症研究和诊断。这项新技术有望彻底改变新的CTC亚群的鉴定，并为每个细胞亚群分配临床有用的特征，如转移潜力。